{"filings":[{"id":1038156,"accession_number":"0001437749-26-020562","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2026-06-15T10:23:55+00:00","items":["5.02","5.07"],"status":"ready","headline":"Filana shareholders approve 2018 Omnibus Incentive Plan amendment; authorized shares increased to 9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5M to 9M (4M added).","Plan term extended through January 31, 2030; repricing of options/SARs explicitly prohibited without stockholder approval.","Three directors elected: Richard J. Barry, Pierre Gravier, Claude Nicaise, M.D. (each ~8.9M for, ~1.5M withheld, ~14.1M broker non-votes).","Ernst & Young ratified as auditor for FY2026 (22.7M for, 1.4M against). Non-binding say-on-pay passed (7.5M for, 2.8M against).","51% of outstanding shares (24.6M of 48.3M) represented at the meeting, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91059,"accession_number":"0001171843-26-003119","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Filana Therapeutics Q1 net loss $10.3M; cash $86.6M, clinical hold on TSC program remains","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.3M ($0.21 per share) vs $23.4M loss in Q1 2025.","Cash and cash equivalents $86.6M at March 31, 2026; no debt.","R&D expenses $4.5M, down 67% due to Alzheimer's program phase-out.","Company still addressing FDA clinical hold for simufilam in TSC-related epilepsy.","Preclinical data in Epilepsia showed simufilam attenuated seizure progression in TSC mouse model."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91058,"accession_number":"0001437749-26-013638","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":[],"status":"ready","headline":"Filana Therapeutics board member Michael O'Donnell resigns effective at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael O'Donnell notified Filana's Board of his resignation on April 22, 2026.","Resignation is effective at the conclusion of the 2026 annual meeting of stockholders.","O'Donnell will continue to serve as a director until the effective date.","Resignation was not due to any disagreement with Company, management, or Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100962,"accession_number":"0001171843-26-001506","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Filana Therapeutics reports 2025 net loss of $91M; cash burn guidance and TSC program clinical hold detailed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $91.0M ($1.88/share) vs $24.3M ($0.53) in 2024; cash $95.5M at Dec 31, 2025.","Est. cash at June 30, 2026 at $47-50M; net cash use H1 2026 $14-17M plus $31.25M litigation settlement payment.","R&D expenses fell 62% to $26.6M after Alzheimer's program phase-out; TSC program on clinical hold since Dec 2025.","G&A expenses $68.8M include $31.3M securities litigation contingency; no insurance recoveries.","Name change to Filana Therapeutics reflects focus on filamin A modulation for TSC-related epilepsy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100961,"accession_number":"0001437749-26-007422","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Cassava Sciences renames to Filana Therapeutics; new ticker FLNA effective March 11","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company changed legal name to Filana Therapeutics, Inc. effective March 10, 2026.","Common stock begins trading on Nasdaq under ticker FLNA on March 11, 2026.","New name reflects strategic focus on modulating filamin A protein for CNS disorders like TSC-related epilepsy.","Amended bylaws modernize provisions for meetings, advance notice, director terms, and uncertificated shares.","No changes to restated certificate of incorporation beyond the name change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100960,"accession_number":"0001171843-26-000922","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"DOJ closes inquiry into Cassava Sciences; ends all government investigations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["DOJ Fraud Section closed previously-disclosed inquiry into research misconduct allegations.","The related indictment in United States v. Wang was dismissed with prejudice on Oct 23, 2025.","Company previously settled SEC negligence charges in Sept 2024 with monetary penalty.","CEO Richard Barry says company remains focused on developing treatment for TSC-related epilepsy.","No further government investigations pending against Cassava Sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117295,"accession_number":"0001437749-25-038605","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cassava Sciences settles securities class action for $31.25M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Company to pay $31.25M into escrow in January 2026 to settle consolidated securities class action.","Settlement covers claims from September 14, 2020 to October 12, 2023; releases all named defendants.","Company had previously recorded a $31.25M loss contingency in Q2 2025 for this litigation.","Settlement is not an admission of fault; formal stipulation to be filed for court approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117288,"accession_number":"0001437749-25-038544","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K/A","filed_at":"2025-12-22T23:59:59+00:00","items":[],"status":"ready","headline":"Cassava Sciences amends 8-K to report Dawn Bir appointed to Compensation Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dawn C. Bir appointed to Compensation Committee effective December 18, 2025.","Amendment to prior 8-K filed October 22, 2025 reporting her board appointment.","No other changes to the original current report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117294,"accession_number":"0001437749-25-038313","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA places Cassava's simufilam TSC-related epilepsy trial on full clinical hold; initiation delayed beyond H1 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA letter on Dec 15, 2025 places proposed simufilam TSC-related epilepsy trial on full clinical hold.","Company must provide additional pre-clinical data and modify the protocol design to address FDA's items.","Initiation of proof-of-concept trial no longer expected in first half of 2026; revised timing depends on FDA review.","Cassava intends to work expeditiously to satisfy FDA's information requests but offers no new timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117293,"accession_number":"0001437749-25-038157","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cassava Sciences awards CEO Barry $355K bonus tied to simufilam TSC epilepsy exploration","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved cash bonuses for 2025: CEO Richard Barry $355,000, CFO Eric Schoen $215,000.","Performance measures include exploring simufilam for Tuberous Sclerosis Complex-related epilepsy.","Other goals: building TSC expertise team and budgeting/expense management.","Bonuses reflect contributions in advancing new potential indication for simufilam beyond Alzheimer's."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117292,"accession_number":"0001437749-25-036710","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cassava Sciences receives FDA request for additional info on simufilam IND for TSC-related epilepsy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted IND for simufilam in tuberous sclerosis complex (TSC)-related epilepsy.","FDA notified Company on Nov 26, 2025, then on Dec 2, 2025, requesting additional info to assess risks.","Company expects formal FDA letter with details; will work collaboratively to address issues.","Proof-of-concept study initiation still targeted for first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117291,"accession_number":"0001171843-25-007222","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cassava Sciences Q3 net loss $10.8M; advances simufilam for TSC epilepsy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.8M ($0.22/share) vs $27.9M loss ($0.58) in Q3 2024; cash $106.1M.","Simufilam proof-of-concept study for TSC-related epilepsy expected to begin H1 2026.","Appointed Joseph Hulihan as CMO (August 2025) and Dawn C. Bir to board (October 2025).","Maintains $31.25M loss contingency for securities litigation settlement; timing unclear.","Cash use guidance for second half 2025 revised downward; year-end cash est. $92-$96M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117290,"accession_number":"0001437749-25-031674","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Federal court dismisses criminal indictment against Cassava's former collaborator Dr. Wang","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Maryland granted unopposed motion to dismiss with prejudice all charges against Dr. Hoau-Yan Wang.","Charges had accused Dr. Wang of causing false grant applications and fabricating research results including Western Blot images.","Dismissal permanently terminates the case; no future charges can be refiled.","Company reaffirms its simufilam program for TSC-related epilepsy based on research at multiple institutions.","Cassava states support for integrity in scientific research and distances from the dismissed allegations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117289,"accession_number":"0001437749-25-031466","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Cassava appoints Dawn Bir to board; plans simufilam TSC-epilepsy study in H1 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dawn Bir appointed as Class I director effective Oct 21, 2025; board expanded to eight members.","Bir is a seasoned biopharma executive with prior roles at Reata, Geron, Soleno, and Pharmacyclics.","Company plans to initiate first clinical study for simufilam in TSC-related epilepsy in first half of 2026.","Bir eligible for standard non-employee director compensation; no material interests or arrangements disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133731,"accession_number":"0001437749-25-028530","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cassava Sciences files 8-K with corporate presentation; no specific facts extracted","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished a corporate presentation dated September 2025 as Exhibit 99.1.","Presentation is available on the Investors section of CassavaSciences.com.","No financial results, guidance, or business updates are disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133730,"accession_number":"0001171843-25-005406","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cassava Sciences Q2 2025 net loss $44.2M, including $31.25M litigation reserve; shifts focus to TSC epilepsy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $44.2M ($0.92 per share) vs net income $6.2M in Q2 2024.","Recorded $31.25M estimated loss contingency for securities litigation settlement.","Alzheimer's program phased out; new focus on simufilam for TSC-related epilepsy - PoC study expected H1 2026.","Cash $112.4M at June 30, 2025; H2 2025 net cash use $47-51M including litigation reserve.","Appointed Dr. Hulihan (CMO), Dr. Bordey (SVP Neuroscience), Dr. Moore (SVP Clin Dev)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133729,"accession_number":"0001171843-25-004981","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cassava Sciences Reports Positive Preclinical Results for Simufilam in TSC-Related Epilepsy Model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Simufilam attenuated seizure progression with significant dose-response in Tsc1 conditional knockout mouse model of TSC-related epilepsy.","Study conducted in collaboration with TSC Alliance and TSC Preclinical Consortium, executed by PsychoGenics, Inc.","First clinical proof-of-concept study for simufilam in TSC-related epilepsy is expected to begin in H1 2026.","Results consistent with prior findings published in Science Translational Medicine from Yale School of Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150447,"accession_number":"0001171843-25-004211","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cassava Sciences simufilam reduces seizures 60% in TSC mouse model; H1 2026 clinical trials planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical data: simufilam reduced seizure frequency by 60% vs. vehicle in focal onset seizure mouse model (p<0.0001).","More mice achieved seizure freedom: 11/32 simufilam vs. 3/29 vehicle (p=0.0343).","Human safety data from 1,929-patient Phase 3 Alzheimer's studies show favorable safety profile with no serious SAEs attributed to drug.","Company plans to initiate first clinical study in TSC-related epilepsy in H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150446,"accession_number":"0001437749-25-018482","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Cassava shareholders reject board declassification; director pay raised","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal to reduce board classification from 3 to 2 classes failed despite 91% of votes cast in favor, lacking 66 2/3% of outstanding shares.","Non-employee director annual cash retainer increased from $10,000 to $40,000; Board Chair gets additional $30,000.","Annual stock option grant for continuing directors raised from 10,000 to 26,500 shares; initial grants rise to 53,000.","Audit, Compensation, and Nominating Committee chairs receive $15,000, $10,000, and $8,000 annual cash fees respectively.","Two directors elected: Robert Anderson, Jr. (5.64M for) and Michael J. O'Donnell (4.54M for) to three-year terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150445,"accession_number":"0001171843-25-002954","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cassava reports Q1 net loss of $23.4M, discontinues Alzheimer's program, pivots to TSC epilepsy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.4M vs net income of $25.0M in Q1 2024; cash and equivalents $117.3M, no debt.","R&D expenses $13.7M (down 16% YoY); G&A $10.9M including $3.0M legal accrual, no insurance recoveries.","Workforce reduced by 10 employees (~33%) in Q1; Alzheimer's program with simufilam to be fully discontinued by end of Q2 2025.","New license from Yale for TSC-related epilepsy; plans to initiate first clinical study in H1 2026.","Appointed Dr. Bordey as SVP Neuroscience and Dr. Moore as SVP Clinical Development; CMO Kupiec retiring May 9."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150444,"accession_number":"0001437749-25-012540","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cassava Sciences CMO retiring; new COO/Legal and SVP Clinical Dev appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Dr. James Kupiec retiring effective May 9, 2025.","R. Christopher Cook promoted to COO & Legal Officer from SVP/GC; base salary raised to $475,000.","Dr. Jack Moore appointed SVP Clinical Development effective April 28, 2025.","CFO Eric Schoen's employment agreement amended and restated; base salary unchanged.","Company advancing simufilam for TSC-related epilepsy after Alzheimer's program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169418,"accession_number":"0001171843-25-001678","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cassava Sciences simufilam Phase 3 trial fails all endpoints; Alzheimer's program discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 REFOCUS-ALZ failed all co-primary, secondary, and biomarker endpoints.","Simufilam showed no significant difference vs placebo on ADAS-COG12 or ADCS-ADL; p-values 0.37-0.67 and 0.16-0.23.","Cassava will discontinue all simufilam Alzheimer's development by Q2 2025.","Company had $128.6M cash at Dec 31, 2024; exploring TSC-related epilepsy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169417,"accession_number":"0001437749-25-007019","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cassava Sciences amends bonus plan; ties CEO payout to FDA approval of simufilam","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendments require Chairman/President/CEO bonus only if FDA approves simufilam, except in Merger Transaction.","Compensation Committee set all previously unallocated cash bonuses to zero and rescinded plan on Feb 13, 2025.","No cash bonuses have been paid to any participant under the CIB Plan through the filing date.","Changes result from shareholder derivative lawsuit settlement approved by Delaware Court of Chancery on Jan 24, 2025.","Market cap milestones up to $5B remain; bonuses deferred until Company has sufficient cash for 24 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169416,"accession_number":"0001171843-25-001183","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cassava Sciences Reports 2024 Financial Results and Provides Business Update","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.3 million ($0.53 per share) in 2024 vs $97.2 million in 2023; cash and equivalents $128.6 million with no debt.","Top-line data for REFOCUS-ALZ, second Phase 3 study of simufilam in Alzheimer's, expected late Q1/early Q2 2025.","RETHINK-ALZ Phase 3 study did not meet co-primary endpoints in November 2024; all Alzheimer's clinical studies discontinued.","License agreement with Yale University to explore simufilam for seizures related to tuberous sclerosis complex (TSC).","G&A expenses rose to $71.8 million in 2024 due to $40 million SEC settlement and higher stock-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169415,"accession_number":"0001437749-25-005338","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cassava Sciences licenses Yale simufilam patent for TSC-related seizures; up to $4.5M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license to issued US method of treatment patent (US 12,186,307) for simufilam in TSC-related epilepsy and other indications.","Financial terms: nominal upfront, up to $4.5M in clinical/regulatory/commercial milestones, tiered low-to-mid single-digit % royalties on net sales.","Based on Yale research (Bordey et al., Science Translational Medicine 2020) showing simufilam reduced seizure frequency in an animal model.","Cassava to prioritize initial development on TSC-related seizures and plans preclinical studies with the TSC Alliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169414,"accession_number":"0001171843-25-000089","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["2.02","8.01","2.05","9.01"],"status":"ready","headline":"Cassava cuts workforce 33% after Phase 3 miss; REFOCUS-ALZ results due Q1/Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 10 employees (33%) with ~$0.4M severance costs in Q1 2025.","Cash and cash equivalents ~$128.6M as of Dec 31, 2024 (unaudited).","Topline data from Phase 3 REFOCUS-ALZ study expected late Q1/early Q2 2025.","Halting planned biomarker analysis of additional plasma samples from prior Phase 2 studies.","RETHINK-ALZ study did not meet co-primary endpoints; REFOCUS-ALZ and OLE study discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186471,"accession_number":"0001171843-24-006545","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cassava Sciences simufilam Phase 3 Alzheimer's trial misses all endpoints; studies halted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Simufilam failed to meet co-primary endpoints: ADAS-COG12 delta -0.39 (p=0.43), ADCS-ADL delta 0.51 (p=0.40).","Company discontinues Phase 3 ReFocus-ALZ and open-label extension studies due to failed ReThink-ALZ results.","Simufilam showed favorable safety profile; serious AEs 13.0% vs 9.0% placebo; 1 death vs 3 in placebo.","Cash and equivalents approx $149M as of Q3 2024; company to evaluate next steps and present data at medical meeting.","Patient demographics balanced; mild-to-moderate AD enrollment; placebo decline less pronounced than expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186470,"accession_number":"0001171843-24-006089","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cassava Sciences reports Q3 net loss $27.9M; RETHINK-ALZ top-line data expected by end-2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $27.9M ($0.58 per share) vs $25.7M ($0.61) in Q3 2023; cash $149M at Sep 30, 2024.","Top-line results from Phase 3 RETHINK-ALZ trial (simufilam) expected before end of 2024.","DSMB recommended both Phase 3 studies continue as planned at Sep 2024 meeting.","Year-end 2024 cash estimated $117-127M; $40M SEC settlement in escrow excluded.","Open-label extension study enrolled over 1,040 patients; 88% opt-in rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186469,"accession_number":"0001437749-24-030845","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Cassava Sciences agrees to $40M SEC settlement; ReTHINK Phase 3 top-line due by year end","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Agreed to pay $40M civil penalty to SEC for negligent disclosures related to Phase 2b study; DOJ not expected to charge company.","ReTHINK Phase 3 (804 patients, 77 sites) completed last patient visit; top-line results expected before year end 2024.","ReFOCUS Phase 3 (1,125 patients) results expected mid-2025; DSMB recommended program continuation without modification.","Separated CEO and Board Chair roles as part of governance enhancements; Rick Barry remains CEO.","Nearly 90% of Phase 3 patients elected open-label extension trial; Phase 2 data showed mild patients stable over 24 months on simufilam."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186468,"accession_number":"0001437749-24-030345","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K/A","filed_at":"2024-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cassava Sciences discloses CEO Richard Barry compensation: $675k base, 600k options at $27.42","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary $675,000, retroactive to July 15, 2024; annual bonus target 60% of base salary.","Stock option award of 600,000 shares at $27.42 exercise price; vests 25% annually starting July 15, 2025.","Termination without cause or for good reason triggers 12-month base salary continuation plus health benefits.","Options granted under 2018 Omnibus Equity Incentive Plan; change-in-control triggers same severance.","Agreement includes standard confidentiality, non-disclosure, and mandatory arbitration provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203056,"accession_number":"0001437749-24-030118","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Cassava Sciences settles SEC probe for $40M; DOJ not expected to charge company","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Agreed to pay $40M civil penalty without admitting or denying SEC allegations of negligence-based disclosure violations.","Resolution covers statements about 2020 Phase 2b simufilam trial; DOJ Criminal Division not expected to bring charges.","Rick Barry appointed Executive Chairman (July 17) and CEO (Sept 6) as part of governance enhancements.","Net cash use H2 2024 estimated $80-90M including penalty; year-end cash projected $117-127M.","Settlement subject to U.S. District Court approval; company had previously reserved $40M loss contingency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203055,"accession_number":"0001437749-24-029380","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cassava Sciences enters consulting agreement with former CEO Remi Barbier","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consulting agreement effective Sep 13, 2024 for one year, with potential one-year extension.","Barbier to provide support for scientific research and regulatory approval at $100 per hour.","Confidentiality, non-disparagement, and cooperation terms apply; severance benefits unchanged.","Barbier may only communicate with CEO or CFO; no contact with other employees without permission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203054,"accession_number":"0001171843-24-005116","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cassava Sciences appoints Rick Barry as CEO; Claude Nicaise becomes Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Barry named CEO effective September 6, 2024; previously Executive Chairman and director since June 2021.","Board separates CEO and Chairman roles; Claude Nicaise, M.D. appointed Chairman.","Dr. Nicaise served as director since Dec 2023; held regulatory roles at Alexion and Bristol-Myers Squibb.","First Phase 3 trial of simufilam (n=804) topline expected by end of 2024; second Phase 3 (n=1,125) by mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203048,"accession_number":"0001437749-24-025654","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K/A","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Cassava Sciences corrects diluted EPS for H1 2024 to ($0.28) from ($1.72)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected diluted EPS for six months ended June 30, 2024 is $(0.28), not $(1.72) as originally reported.","No other financial figures in the August 8, 2024 earnings release are affected by this amendment.","Corrected figure matches diluted EPS reported in the Form 10-Q filed on August 8, 2024.","Amendment filed on August 9, 2024; initial 8-K remains unchanged except for the EPS correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203053,"accession_number":"0001171843-24-004561","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"Cassava Sciences reports Q2 net income, $40M SEC loss contingency, Phase 3 readout timeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net income $6.2M vs net loss $26.4M in 2023, driven by non-cash warrant gain.","Recorded $40M loss contingency for advanced discussions to resolve SEC investigation.","Cash $207.3M at June 30, 2024; no debt; warrants fully exercised.","Phase 3 RETHINK-ALZ top-line data expected by end of 2024; REFOCUS-ALZ mid-2025.","Audit Committee vacancy due to director death; Nasdaq noncompliance; cure until Aug 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203052,"accession_number":"0001437749-24-023128","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Cassava Sciences Executive Chairman outlines Phase 3 trial timelines and transparency pledge","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First Phase 3 simufilam trial (804 patients) to read out by Dec 2024; second by June 2025.","Rick Barry takes roles of Executive Chairman and principal executive officer until new CEO.","Company commits to rigorous science and timely disclosure of material news, good or bad.","Trial data held by Premier Research; biostatistics by Pentara – Cassava won't see results early."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203051,"accession_number":"0001437749-24-022952","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cassava Sciences settles shareholder derivative suit; CEO bonus now tied to FDA approval of simufilam","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement modifies CEO Remi Barbier's $74.9M bonus: payment requires FDA approval of simufilam or recalculation upon sale.","Corporate governance reforms: new Compensation Disclosure Committee, retention of compensation consultant by board.","Court approval hearing set for Sept 9, 2024; settlement includes dismissal of derivative claims with prejudice.","Cassava also achieved removal of non-employee directors from bonus plan and appointment of three independent directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203050,"accession_number":"0001437749-24-022876","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.02","7.01","8.01"],"status":"ready","headline":"Cassava Sciences CEO Remi Barbier resigns; Rick Barry named Executive Chairman; CEO search begins","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO/President Remi Barbier resigns effective Sep 13, 2024; also resigns as Chairman and Board member immediately.","SVP Neuroscience Lindsay Burns steps down; enters 1-year consulting agreement at $500/hour; receives $0.5M severance.","Independent director Rick Barry appointed Executive Chairman and principal executive officer; CEO search launched.","Board adds Pierre Gravier as Audit Committee Chair, Robert Anderson as Nominating & Governance Committee Chair.","Company pledges enhanced transparency: quarterly analyst calls and timely posting of Phase 3 trial results to clinicaltrials.gov."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203049,"accession_number":"0001493152-24-025725","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cassava discloses potential unblinding in Phase 2b study; collaborator indicted by DOJ","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DOJ indicted Dr. Wang for allegedly causing false statements to NIH about simufilam; company terminated his consulting.","Internal investigation found senior employee may have unblinded Dr. Wang to some Phase 2b participants before bioanalysis.","Reported Phase 2b CANTAB analysis excluded ~42% of subjects for episodic memory; results reflect smaller analysis set.","Phase 3 trials fully enrolled (~1,900 patients), remain blinded; independent firms will handle bioanalysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219338,"accession_number":"0001437749-24-018029","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cassava Sciences awards $850k in discretionary bonuses to execs; CFO gets change-in-control severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Remi Barbier receives $500k discretionary cash bonus.","CFO Eric Schoen receives $250k bonus; employment amended to include 12-month severance after change in control.","General Counsel R. Christopher Cook and CMO James Kupiec each receive $50k bonus.","Change in control defined as acquisition of 51% or more of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219337,"accession_number":"0001437749-24-016260","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cassava Sciences stockholders elect three directors, ratify auditor, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of ~62% (26,979,468 shares) represented at May 9, 2024 annual meeting.","Three director nominees elected: Barbier (10.8M for), Robertson (8.9M for), Scannon (10.9M for).","Ratification of Ernst & Young as auditor approved (26.5M for, 0.4M against).","Advisory vote on 2023 executive compensation approved (9.4M for, 1.3M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219336,"accession_number":"0001171843-24-002765","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cassava Sciences Q1 net income $25M; Phase 3 Alzheimer's trials on track with >1,900 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $25.0M vs net loss $24.3M in Q1 2023; non-cash warrant gain drove the swing.","$126.3M in gross proceeds from warrant exercise; cash & equivalents $124.2M, no debt as of March 31.","Over 1,900 patients randomized across two Phase 3 simufilam trials; >735 patients have completed.","Top-line data for 52-week RETHINK-ALZ expected year-end 2024; 76-week REFOCUS-ALZ data mid-2025.","Q1 R&D spend $16.2M, down from $22.1M YoY; H1 2024 operating cash burn guided at $35-45M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219335,"accession_number":"0001171843-24-002669","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cassava Sciences raises over $125M from warrant exercises; ~5.7M shares at $22","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds over $125M from cash exercises of warrants; ~5.7M common shares issued at $22.00 per share.","Net proceeds estimated at over $123M after advisory fees and expenses.","Proceeds to fund working capital and continued development of Alzheimer's drug simufilam.","Warrants distributed to shareholders, last exercise deadline May 6, 2024; remaining warrants redeemed at $0.001 each.","B. Dyson Capital Advisors acted as exclusive financial advisor on the warrant distribution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219334,"accession_number":"0001171843-24-002403","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SAVAW warrants last trade May 2; final exercise May 6 at $33 for 1.5 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last trading day for SAVAW warrants on NASDAQ: end of day May 2, 2024.","Final cash-exercise deadline: 5pm ET May 6, 2024; exercise price $33 per warrant for 1.5 common shares (~$22/share).","Unexercised warrants redeemed on May 7, 2024 for $0.001 each.","Company offers Notice of Guaranteed Delivery for delayed warrant exercises through May 6."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219333,"accession_number":"0001171843-24-002020","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cassava Sciences sets May 6 final warrant exercise deadline; unexercised warrants redeemed for $0.001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May 6, 2024 at 5pm ET is last day to exercise warrants (distributed Jan 3); unexercised warrants redeemed May 7 for $0.001 each.","Each warrant entitles holder to purchase 1 share at $33 plus 0.5 bonus share; effective price ~$22 per share for 1.5 shares.","Company receives cash only from exercised warrants; holders may also sell warrants on open market before deadline.","Warrants issued as 4 warrants per 10 shares held on Dec 22, 2023 record date, rounded down.","Nominal redemption price of $0.001 per warrant applies after deadline; warrants will cease to exist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239165,"accession_number":"0001171843-24-001035","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cassava Sciences reports FY2023 net loss of $97.2M; Phase 3 topline data expected year-end 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $97.2M ($2.32/share) vs $76.2M ($1.90) in 2022; R&D expenses $89.4M.","Cash and equivalents $121.1M at 12/31/23; $21.8M raised in 2024 from warrant exercises.","Over 555 patients completed Phase 3 studies; topline data for 52-week trial expected year-end 2024.","Internal investigation found no evidence substantiating allegations of research misconduct.","Net cash used in operations $82M in 2023; expected $35-45M in H1 2024."],"consensus_eps_estimate":-0.6681,"consensus_eps_actual":-2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239164,"accession_number":"0001171843-24-000648","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cassava Sciences: simufilam shows stable ADAS-Cog in mild Alzheimer's over 24 months","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Mild Alzheimer's patients on continuous simufilam (n=47) averaged 0.07 point ADAS-Cog change (±1.51 SE) from baseline to month 24.","Non-continuous mild group (n=40) declined 1.04 points on ADAS-Cog (±1.65 SE); largest separation during placebo withdrawal.","Moderate Alzheimer's patients on continuous simufilam (n=32) declined 11.05 points on ADAS-Cog (±1.91 SE).","Simufilam 100 mg twice daily safe and well tolerated; no drug-related serious adverse events; common TEAEs were COVID-19 and UTI.","Phase 3 top-line results expected: 52-week study year-end 2024; 76-week study mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239163,"accession_number":"0001493152-24-000209","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cassava Sciences distributes warrants to common shareholders; each 10 shares get 4 warrants exercisable at $33","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Distribution of warrants to holders of record as of Dec 22, 2023, at ratio of 4 warrants per 10 common shares.","Each warrant allows purchase of one share at $33, plus a bonus of 0.5 additional shares if exercised before bonus expiry.","Warrants expire Nov 15, 2024; redeemable by company after Apr 15, 2024 at 1/10 of $0.01 per warrant.","Warrants expected to trade on Nasdaq under ticker SAVAW starting Jan 4, 2024.","Prospectus supplement filed to register 24,342,150 shares of common stock for issuance upon warrant exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256677,"accession_number":"0001437749-23-034146","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":[],"status":"ready","headline":"Cassava Sciences declares warrant distribution; holders get 4 warrants per 10 shares, exercise price $33","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders of record Dec 22, 2023 receive 4 warrants per 10 shares, free of charge; distributed Jan 3, 2024.","Each warrant exercisable for one share at $33; warrants expected to trade on Nasdaq under ticker 'SAVAW'.","Early exercise before Bonus Share Expiration yields additional 0.5 common share per warrant, effective price ~$22.","Warrants expire Nov 15, 2024; redeemable by company after Apr 15, 2024 on 20 days' notice.","Proceeds from warrant exercises to fund Phase 3 clinical trials of oral simufilam for Alzheimer's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256676,"accession_number":"0001437749-23-034076","cik":1069530,"company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":[],"status":"ready","headline":"Cassava Sciences expands board to 9 with three new directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Dr. Claude Nicaise, Pierre Gravier, and Robert Anderson, Jr. effective Dec 6, 2023.","Board expanded from 6 to 9 members; Anderson (Class I), Nicaise and Gravier (Class II).","Nicaise led regulatory/clinical roles resulting in 14 drug approvals; Gravier is CFO of PTC Therapeutics.","Anderson is former FBI Executive Assistant Director and cybersecurity expert.","No committees assigned; none have material interests in reportable transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":72461841.48936172,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-12-11T23:59:59+00:00|256676"}